CN116217545A - 一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 - Google Patents
一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 Download PDFInfo
- Publication number
- CN116217545A CN116217545A CN202111476421.8A CN202111476421A CN116217545A CN 116217545 A CN116217545 A CN 116217545A CN 202111476421 A CN202111476421 A CN 202111476421A CN 116217545 A CN116217545 A CN 116217545A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- compounds
- preparation
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000000523 sample Substances 0.000 title claims abstract description 32
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 238000003384 imaging method Methods 0.000 claims abstract description 17
- 230000002107 myocardial effect Effects 0.000 claims abstract description 17
- 238000012879 PET imaging Methods 0.000 claims abstract description 16
- -1 indolylethylquinoline salts Chemical class 0.000 claims abstract description 14
- 230000010412 perfusion Effects 0.000 claims abstract description 14
- 239000012216 imaging agent Substances 0.000 claims abstract description 10
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 8
- 229940126214 compound 3 Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 16
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 claims description 15
- 229940125782 compound 2 Drugs 0.000 claims description 14
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 10
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 8
- RZRQBRMLTFIIND-UHFFFAOYSA-N 1,4-dimethyl-2h-pyridine Chemical class CN1CC=C(C)C=C1 RZRQBRMLTFIIND-UHFFFAOYSA-N 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 229910020366 ClO 4 Inorganic materials 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 238000006000 Knoevenagel condensation reaction Methods 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 8
- 230000002438 mitochondrial effect Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 5
- 239000012217 radiopharmaceutical Substances 0.000 abstract description 2
- 229940121896 radiopharmaceutical Drugs 0.000 abstract description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 28
- 238000005481 NMR spectroscopy Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 21
- PEENKJZANBYXNB-UHFFFAOYSA-N 5-bromo-1h-indole-3-carbaldehyde Chemical compound BrC1=CC=C2NC=C(C=O)C2=C1 PEENKJZANBYXNB-UHFFFAOYSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- 239000012265 solid product Substances 0.000 description 11
- HUTXVUPGARJNHM-UHFFFAOYSA-N 1-(2-chloroethoxy)ethanol Chemical compound CC(O)OCCCl HUTXVUPGARJNHM-UHFFFAOYSA-N 0.000 description 9
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 9
- 238000013170 computed tomography imaging Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- ZFAGSDJDJKIGEV-UHFFFAOYSA-N 1,4-dimethyl-2H-pyridine hydroiodide Chemical compound I.CN1CC=C(C)C=C1 ZFAGSDJDJKIGEV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- KECMLGZOQMJIBM-UHFFFAOYSA-N 2-[2-(2-chloroethoxy)ethoxy]ethanol Chemical compound OCCOCCOCCCl KECMLGZOQMJIBM-UHFFFAOYSA-N 0.000 description 4
- CZWNQQJOJRLUSS-UHFFFAOYSA-N 3-[2-(1-methylpyridin-1-ium-4-yl)ethenyl]-1h-indole;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1\C=C\C1=CNC2=CC=CC=C12 CZWNQQJOJRLUSS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YUAJKGBLPVLADK-UHFFFAOYSA-N 5-fluoro-1h-indole-3-carbaldehyde Chemical compound FC1=CC=C2NC=C(C=O)C2=C1 YUAJKGBLPVLADK-UHFFFAOYSA-N 0.000 description 2
- TUWARWGEOHQXCO-UHFFFAOYSA-N 5-methoxyindole-3-carbaldehyde Chemical compound COC1=CC=C2NC=C(C=O)C2=C1 TUWARWGEOHQXCO-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- SHBPWRKNNIMXFT-UHFFFAOYSA-N CN1CC=C(C=C1)C.Cl(=O)(=O)(=O)O Chemical compound CN1CC=C(C=C1)C.Cl(=O)(=O)(=O)O SHBPWRKNNIMXFT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YLYPIBBGWLKELC-RMKNXTFCSA-N 2-[2-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC(=C(C#N)C#N)C=C(C)O1 YLYPIBBGWLKELC-RMKNXTFCSA-N 0.000 description 1
- NVBCFOQYDFKXJJ-UHFFFAOYSA-N 3-formyl-1h-indole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(C=O)=CNC2=C1 NVBCFOQYDFKXJJ-UHFFFAOYSA-N 0.000 description 1
- QUTHCURCAWPHIN-UHFFFAOYSA-N 4-[2-(1-methyl-5-nitroimidazol-2-yl)ethynyl]pyrimidin-2-amine Chemical compound C1=C([N+]([O-])=O)N(C)C(C#CC=2N=C(N)N=CC=2)=N1 QUTHCURCAWPHIN-UHFFFAOYSA-N 0.000 description 1
- ZBXFRJNUAWOOCU-UHFFFAOYSA-N 5-(dimethylamino)-1h-indole-3-carbaldehyde Chemical compound CN(C)C1=CC=C2NC=C(C=O)C2=C1 ZBXFRJNUAWOOCU-UHFFFAOYSA-N 0.000 description 1
- CWCYUOSLRVAKQZ-UHFFFAOYSA-N 6-fluoro-1h-indole-3-carbaldehyde Chemical compound FC1=CC=C2C(C=O)=CNC2=C1 CWCYUOSLRVAKQZ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/04—Luminescent, e.g. electroluminescent, chemiluminescent materials containing natural or artificial radioactive elements or unspecified radioactive elements
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用。该探针结构如式Ⅰ所示,为18F或19F取代的吲哚乙烯喹啉盐类(F16)化合物。该类化合物具有制备简单、化学稳定性好、放射化学纯度高,具有荧光等优点,可作为线粒体成像相关的心肌灌注和肿瘤PET显像剂或荧光显像剂应用在放射性药物化学和荧光分子影像技术领域中。
Description
技术领域
本发明涉及放射性药物化学和荧光分子影像技术领域,具体地说,涉及一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用。
背景技术
线粒体是细胞生命活动的能量供应工厂,是多种生理生化过程的发生场所。线粒体的数量与细胞的能量需求有关,新陈代谢旺盛的器官和组织,如心脏、肿瘤组织,其细胞内含有大量线粒体。大量研究表明,线粒体功能异常与多种疾病相关,如肿瘤、心衰、糖尿病等。因此,线粒体靶向成像可以为研究线粒体功能和相关疾病的诊疗提供检测依据。
心脏和肿瘤组织代谢活跃,为其供应能量的线粒体具有更高的线粒体膜电位,一些离域亲脂性阳离子化合物(DLCs)在线粒体膜电位的驱使下,利用分子亲脂性特性进入线粒体基质内,达到线粒体富集效果。目前以线粒体为靶点的亲脂性阳离子在肿瘤分子影像探针、抗肿瘤药物和心肌灌注成像研究领域,已成为一大热点。但上述亲脂性阳离子探针多以荧光试剂居多,正电子探针开发相对较少,且多以三苯基膦鎓盐(TPP)为主,如18F-FBnTP(Nature 2019,575(7782),380-384.)、18F-FPEGBnTP(J Labelled Comp Radiopharm 2016,59(3),117-123)、18F-FTPMP(Eur.J.Med.Chem.2016,118,90-97)、18F-FMBTP(Mol.Pharm.2014,11(11),3823-3831)和18F-FPTP(ACS Med.Chem.Lett.2014,5(10),1124-1128)等,其它结构如罗丹明衍生物为代表的18F-FERhB(Nucl.Med.Biol.2010,37(3),365-370)、18F-Rhodamin 6G(Medchemcomm 2017,8(10),1891-1896)亦有报道。
但广泛应用于肿瘤线粒体靶向的吲哚乙烯喹啉盐F16类化合物(Cancer Cell2002,2(1),29-42;Chem.Commun.(Camb.)2014,50(64),8919-8922;Chemical Science2019,10(34),7946-7951)却未有正电子探针研究报道。F16类化合物具有高度疏水性,可以跨过细胞膜和线粒体膜的疏水屏障,在线粒体膜电位较高的心肌细胞和肿瘤细胞高度富集,同时F16类化合物本身具备荧光特性,非常适合低成本的荧光成像筛选,以及临床荧光成像手术导航。因此,开发线粒体靶向的吲哚乙烯喹啉盐F16类化合物的正电子探针为拓宽心肌灌注和肿瘤PET(正电子发射型计算机断层显像)分子探针领域具有重要意义。
发明内容
本发明的一个目的是提供一类18F或19F标记或取代的吲哚乙烯喹啉盐F16类化合物。
本发明的另一个目是提供所述化合物的制备方法。
本发明的再一个目的是提供所述化合物作为线粒体靶向的正电子发射或荧光探针的应用。
为实现上述目的,本发明采用以下技术方案:
根据本发明的一个方面,提供一种式I化合物:
其中:n为0,1,2,3或4;
X-为任意形式阴离子,优选为I-,Br-,BF4 -或ClO4 -;
R1和R2各自独立地选自氢、卤素、氰基、硝基、C1-C6烷氧基、-NR4R5,其中,R4和R5各自独立地选自H、C1-C6烷基,或者R4和R5与相连的N共同构成取代或未取代的5-7元饱和杂环基,所述取代的取代基选自C1-C6烷基、C1-C6烷氧基,所述5-7元饱和杂环基含有1或2个选自N、O、S的杂原子,特别地,-NR4R5选自二(C1-C6烷基)氨基、吡咯基、哌啶基、未取代或C1-C6烷基取代的哌嗪基、吗啉基,
优选R1和R2各自独立地为:
R3为18F或19F。
具体地,根据本发明的式I化合物优选选自以下化合物:
本发明进一步提供所述的式I化合物的制备方法,其制备路线如下:
所述方法通过如下方法一或方法二进行,
方法一
包括如下步骤:
(a)吲哚3-甲醛化合物1和Hal-(CH2CH2O)nC2H5OH发生亲核取代反应得到化合物2;
(b)化合物2与对甲苯磺酰氯发生酯化反应得到化合物3;
(c)化合物3在氨基聚醚(K2.2.2)存在下与18F-F-发生亲核取代反应得到18F取代的化合物18F-4;
(d)化合物18F-4与1,4-二甲基吡啶盐发生Knoevenagel缩合反应得到终产物18F-F16;
方法二
包括如下步骤:
(a)吲哚3-甲醛化合物1和Hal-(CH2CH2O)nC2H5OH发生亲核取代反应得到化合物2;
(b)化合物2与对甲苯磺酰氯发生酯化反应得到化合物3;
(e)化合物3与四丁基氟化铵发生亲核取代反应得到19F取代的化合物19F-4,
(f)化合物19F-4与1,4-二甲基吡啶盐发生Knoevenagel缩合反应得到终产物19F-F16;
其中n,R1,R2,X-分别如上所定义,Hal表示卤素,特别是氯或溴。
在一实施方式中,所述方法包括如下步骤:
(1)吲哚3-甲醛化合物1和碳酸钾加入到N,N-二甲基甲酰胺中,并加入Hal-(CH2CH2O)nC2H5OH(例如2-溴乙醇,2-氯乙氧基乙醇,2-[(2-氯乙氧基)乙氧基]乙醇,或2-[2-[2-(2-氯乙氧基)乙氧基]乙氧基]乙醇)和少量碘化钾,90℃搅拌反应8h,反应完毕后冷却、稀释、对稀释溶液萃取、洗涤有机层、干燥、过滤、浓缩并纯化,得到中间体化合物2;
(2)将化合物2、三乙胺和少量4-二甲氨基吡啶溶于干燥二氯甲烷中,冰水浴条件下分批次加入对甲苯磺酰氯,加入完毕后恢复室温反应4h,反应完毕后稀释、对稀释溶液萃取、洗涤有机层、干燥,过滤并浓缩纯化,得到标记前体化合物3;
(3-1)将化合物3和四丁基氟化铵在无水四氢呋喃或无水乙腈溶液中加热90℃反应,得19F取代的化合物19F-4,或
(3-2)将氨基聚醚(K2.2.2)、碳酸钾、18F-F-和化合物3在无水乙腈中100℃反应10min,得到18F取代的化合物18F-4;
(4-1)将上述(3-1)得到的19F取代的化合物19F-4、1倍当量的1,4-二甲基吡啶盐和0.2当量的哌啶在氮气保护下无水甲醇中回流加热过夜,冷却后重结晶得到终产物19F-F16,或
(4-2)将上述(4-1)得到的18F取代的化合物18F-4、1,4-二甲基吡啶盐和哌啶在无水乙腈中100℃反应10min,冷却后经分离纯化得到终产物18F-F16,
其中n,R1,R2,X-分别如上所述,Hal表示卤素。
在一实施方式中,本发明提供所述的19F-F16的制备步骤如下:
(1)将吲哚3-甲醛化合物1和碳酸钾加入到20mL N,N-二甲基甲酰胺中,并加入2-溴乙醇或2-氯乙氧基乙醇或2-[(2-氯乙氧基)乙氧基]乙醇或2-[2-[2-(2-氯乙氧基)乙氧基]乙氧基]乙醇和少量碘化钾,90℃搅拌反应8h,反应完毕待冷却后,用饱和氯化铵溶液稀释反应液,并用乙酸乙酯萃取3次,有机层用饱和盐水洗涤,无水硫酸钠干燥,过滤并浓缩经过柱层析纯化,得到中间体化合物2;
(2)将化合物2、三乙胺和少量4-二甲氨基吡啶溶于50mL干燥二氯甲烷中,冰水浴条件下分批次加入对甲苯磺酰氯,加入完毕后恢室温反应4h,反应完毕后碳酸氢钠溶液稀释,并用乙酸乙酯萃取3次,有机层分别用稀盐酸和饱和盐水洗涤,无水硫酸钠干燥,过滤并浓缩经过柱层析纯化,得到标记前体化合物3;
(3)将化合物3和四丁基氟化铵在无水四氢呋喃或无水乙腈溶液中加热反应,可得19F取代的吲哚-3-甲醛化合物19F-4;
(4)将上述得到的19F取代化合物19F-4、1,4-二甲基吡啶盐和0.2当量的哌啶在氮气保护下无水甲醇中回流加热过夜,冷却后重结晶得到终产物19F-F16。
在另一实施方式中,本发明提供所述的正电子探针18F-F16的制备步骤如下:
(1)将吲哚3-甲醛化合物1和碳酸钾加入到20mL N,N-二甲基甲酰胺中,并加入2-溴乙醇或2-氯乙氧基乙醇或2-[(2-氯乙氧基)乙氧基]乙醇或2-[2-[2-(2-氯乙氧基)乙氧基]乙氧基]乙醇和少量碘化钾,90℃搅拌反应8h,反应完毕待冷却后,用饱和氯化铵溶液稀释反应液,并用乙酸乙酯萃取3次,有机层用饱和盐水洗涤,无水硫酸钠干燥,过滤并浓缩经过柱层析纯化,得到中间体化合物2;
(2)将化合物2、三乙胺和少量4-二甲氨基吡啶溶于50mL干燥二氯甲烷中,冰水浴条件下分批次加入对甲苯磺酰氯,加入完毕后恢室温反应4h,反应完毕后碳酸氢钠溶液稀释,并用乙酸乙酯萃取3次,有机层分别用稀盐酸和饱和盐水洗涤,无水硫酸钠干燥,过滤并浓缩经过柱层析纯化,得到标记前体化合物3;
(3’)将氨基聚醚(K2.2.2)、碳酸钾、18F-F-和前体化合物3在无水乙腈中100℃反应10min,得到18F标记化合物4;
(4’)将上述得到的18F标记化合物4、1,4-二甲基吡啶盐和哌啶在无水乙腈中100℃反应10min,冷却后经半制备高效液相分离得到标记终产物18F-F16,其可再经氮吹干燥,加入1mL无菌生理盐水稀释备用。
根据本发明,1,4-二甲基吡啶盐可以选自1,4-二甲基吡啶溴化物、1,4-二甲基吡啶碘化物、1,4-二甲基吡啶高氯酸盐、1,4-二甲基吡啶四氟硼酸盐。
根据本发明的另一方面,本发明还提供所述的式I化合物作为线粒体靶向的正电子发射或荧光探针的应用,特别是在心肌灌注和肿瘤显像中的应用,尤其是在制备心肌灌注PET显像剂或肿瘤PET显像剂或者在制备心肌灌注荧光显像剂或肿瘤荧光显像剂中的应用。
根据本发明的18F标记的F16类化合物,制备简单、化学稳定性好、放射化学纯度高、能够作为正电子发射探针应用在心肌灌注和肿瘤PET显像领域。
根据本发明的19F取代的F16类化合物,制备简单、化学稳定性好、具有荧光等优点,能够作为荧光探针应用在活体成像中,例如在心肌灌注和肿瘤荧光显像领域。
该类化合物具有制备简单、化学稳定性好、放射化学纯度高,具有荧光等优点,在18F标记后,PET/CT显像结果中表明,在靶组织心脏或肿瘤中摄取较高,其有望应用于临床,发展为一类新型的心肌灌注和肿瘤PET显像剂。
附图说明
图1示意性地示出了根据本发明的化合物作为正电子发射或荧光探针在小鼠中的线粒体靶向的显像示意图;
图2为实施例12制备的18F-5BEE-F16的放化纯度HPLC图谱;
图3为实施例13制备的18F-5MEF-F16的放化纯度HPLC图谱;
图4为实施例14制备的18F-6FEF-F16的放化纯度HPLC图谱;
图5为实施例13制备的18F-5MEF-F16的体外稳定性实验HPLC图谱(a:PBS中孵育1h,b:PBS中孵育2h,c:FBS中孵育1h,d:FBS中孵育2h,);
图6为实施例13制备的18F-5MEF-F16在正常Balb/c小鼠体内心肌灌注micro-PET/CT显像效果图(箭头指示为心脏);
图7为实施例14制备的18F-6FEF-F16在4T1荷瘤小鼠体内肿瘤micro-PET/CT显像效果图(箭头指示为肿瘤);
图8为实施例1-11所制备的11种19F-F16化合物在正常小鼠离体组织荧光成像图;
图9为实施例7制备的19F-EE-F16在4T1荷瘤小鼠活体荧光成像图(箭头指示为肿瘤)。
具体实施方式
除特殊说明外,本申请中所采用的原料、试剂、试验动物等均为本领域常规原料、试剂、试验动物且市售可得,动物试验遵守实验动物伦理要求,所采用的设备和方法均为本领域常规设备和方法。
实施例1:19F-5BEE-F16的制备
(1)合成实施例1中间体2
将5-溴吲哚-3-甲醛(2.24g,10mmol)和碳酸钾(2.07g,15mmol)加入到20mL N,N-二甲基甲酰胺中,并加入2-氯乙氧基乙醇(1.62g,13mmol)和少量碘化钾(83mg,0.5mmol),90℃搅拌反应8h,反应完毕待冷却后,用饱和氯化铵溶液稀释反应液,并用乙酸乙酯萃取3次,有机层用饱和盐水洗涤,无水硫酸钠干燥,过滤并浓缩经过柱层析纯化,得到白色固体2.5g,产率80%。1H NMR(400MHz,CDCl3)δ9.93(s,1H),8.45(d,J=1.9Hz,1H),7.81(s,1H),7.41(dd,J=8.7,2.0Hz,1H),7.25(d,J=8.7Hz,1H),4.34(t,J=5.1Hz,2H),3.87(t,J=5.1Hz,2H),3.72–3.65(m,2H),3.53(t,J=4.7Hz,2H),1.90(t,J=5.8Hz,1H).13C NMR(101MHz,CDCl3)δ184.4,139.7,136.0,127.0,126.8,124.8,117.7,116.6,111.4,72.6,69.3,61.7,47.3.结构如下:
(2)合成实施例1中间体3
将上步中间体2(1.56g,5mmol)、三乙胺(0.76g,7.5mmol)和少量4-二甲氨基吡啶(61mg,0.5mmol)溶于50mL干燥二氯甲烷中,冰水浴条件下分批次加入对甲苯磺酰氯(1.24g,6.5mmol),加入完毕后恢复室温反应4h,反应完毕后碳酸氢钠溶液稀释,并用乙酸乙酯萃取3次,有机层分别用稀盐酸和饱和盐水洗涤,无水硫酸钠干燥,过滤并浓缩经过柱层析纯化,得到标记前体化合物3为白色固体1.72g,产率74%。1H NMR(400MHz,CDCl3)δ9.93(s,1H),8.46(d,J=2.0Hz,1H),7.77(s,1H),7.72(d,J=8.3Hz,2H),7.38(dd,J=8.8,2.0Hz,1H),7.31(d,J=8.1Hz,2H),7.21(d,J=8.7Hz,1H),4.29(t,J=5.0Hz,2H),4.11–4.06(m,2H),3.80(t,J=5.0Hz,2H),3.63–3.57(m,2H),2.44(s,3H).13C NMR(101MHz,CDCl3)δ184.6,145.1,140.0,135.9,132.8,129.9,127.8,126.9,126.8,124.9,117.7,116.5,111.4,69.5,68.9,68.8,47.1,21.7.结构如下:
(3)合成实施例1中间体19F-4
将上步中间体3(0.93g,2mmol)、四丁基氟化铵(6mmol)溶于10mL无水乙腈中,90℃加热反应4h,反应结束后,减压旋蒸除去溶剂,经过柱层析纯化,得到标记前体化合物19F-4为淡黄色固体0.54g,产率86%。1H NMR(400MHz,CDCl3)δ9.86(s,1H),8.38(d,J=2.0Hz,1H),7.76(s,1H),7.33(dd,J=8.7,2.0Hz,1H),7.19(d,J=8.7Hz,1H),4.51(t,J=3.7Hz,1H),4.39(t,J=3.9Hz,1H),4.28(t,J=5.0Hz,2H),3.83(t,J=5.0Hz,2H),3.65(t,J=3.9Hz,1H),3.57(t,J=3.9Hz,1H).13C NMR(101MHz,CDCl3)δ184.5,140.2,136.0,126.8,126.7,124.6,117.5,116.4,111.6,83.8,82.1,70.6,70.4,69.5,47.2.结构如下:
(4)合成实施例1产物19F-5BEE-F16
将上述19F-4化合物(0.31g,1mmol)分别与1倍当量1,4-二甲基吡啶碘化物和0.2倍当量哌啶加入到10mL无水甲醇中,氮气保护下反应液回流加热过夜,通过TLC监控反应。待反应结束后,反应液置于-20℃冰箱冷却,伴有沉淀物生成,过滤收集沉淀物,冷甲醇洗涤,最后经乙腈重结晶得橘黄色固体产物0.25g,产率47%。1H NMR(400MHz,DMSO-d6)δ8.72(d,J=6.6Hz,2H),8.36(d,J=1.9Hz,1H),8.23(d,J=16.3Hz,1H),8.17(d,J=6.8Hz,2H),8.06(s,1H),7.65(d,J=8.7Hz,1H),7.43(dd,J=8.7,1.9Hz,1H),7.27(d,J=16.3Hz,1H),4.57–4.51(m,1H),4.46(t,J=5.1Hz,2H),4.43–4.39(m,1H),4.19(s,3H),3.82(t,J=5.1Hz,2H),3.73–3.65(m,1H),3.63–3.58(m,1H).13C NMR(101MHz,DMSO-d6)δ154.3,144.8,136.6,135.7,135.0,127.8,125.8,123.0,122.4,121.6,118.2,114.8,113.8,112.7,84.3,82.6,70.1,70.0,69.5,46.8,46.7.HRMS(ESI)m/z:[M-I]+calculated for C20H21BrFN2O:403.0816,405.0796,found:403.0815,405.0792.结构如下:
实施例2:19F-5BEF-F16的制备
合成方法同实施例1,不同在于,用2-溴乙醇代替2-氯乙氧基乙醇,重结晶得橘黄色固体产物0.21g。1H NMR(400MHz,DMSO-d6)δ8.73(d,J=6.6Hz,2H),8.39(d,J=1.9Hz,1H),8.24(d,J=16.3Hz,1H),8.18(d,J=6.6Hz,2H),8.08(s,1H),7.65(d,J=8.7Hz,1H),7.45(dd,J=8.8,1.8Hz,1H),7.30(d,J=16.3Hz,1H),4.84(t,J=4.6Hz,1H),4.72(t,J=4.5Hz,1H),4.67(t,J=4.6Hz,1H),4.60(t,J=4.6Hz,1H),4.20(s,3H).13C NMR(101MHz,DMSO-d6)δ154.3,144.8,136.5,135.3,134.8,127.9,126.0,123.0,122.5,118.6,114.9,113.7,113.0,83.8,82.2,47.3,47.1,46.9.HRMS(ESI)m/z:[M-I]+calculated forC18H17BrFN2:359.0554,361.0534,found:359.0553,361.0526.
实施例3:19F-5MEE-F16的制备
合成方法同实施例1,不同在于,采用5-甲氧基吲哚-3-甲醛代替5-溴吲哚-3-甲醛,重结晶得红色固体产物0.22g。1H NMR(400MHz,DMSO-d6)δ8.67(d,J=6.7Hz,2H),8.23(d,J=16.2Hz,1H),8.18–8.09(m,2H),7.96(s,1H),7.61(d,J=2.5Hz,1H),7.56(d,J=8.9Hz,1H),7.18(d,J=16.2Hz,1H),6.95(dd,J=8.9,2.4Hz,1H),4.58–4.50(m,1H),4.46–4.38(m,3H),4.17(s,3H),3.88(s,3H),3.81(t,J=5.1Hz,2H),3.70–3.65(m,1H),3.63–3.57(m,1H).13C NMR(101MHz,DMSO-d6)δ155.8,154.6,144.5,136.1,135.5,132.9,126.8,122.0,116.8,112.9,112.6,112.4,103.6,84.3,82.6,70.1,70.0,69.5,56.3,46.7.HRMS(ESI)m/z:[M-I]+calculated for C21H24FN2O2:355.1817,found:355.1812.
实施例4:19F-5MEE-F16的制备
合成方法同实施例1,不同在于,采用5-甲氧基吲哚-3-甲醛代替5-溴吲哚-3-甲醛,2-溴乙醇代替2-氯乙氧基乙醇,重结晶得橘黄色固体产物0.22g。1H NMR(400MHz,DMSO-d6)δ8.68(d,J=6.9Hz,2H),8.23(d,J=16.2Hz,1H),8.17–8.09(m,2H),7.99(s,1H),7.62(d,J=2.4Hz,1H),7.56(d,J=8.9Hz,1H),7.21(d,J=16.2Hz,1H),6.97(dd,J=8.9,2.4Hz,1H),4.83(t,J=4.6Hz,1H),4.71(t,J=4.6Hz,1H),4.62(t,J=4.6Hz,1H),4.55(t,J=4.7Hz,1H),4.18(s,3H),3.88(s,3H).13C NMR(101MHz,DMSO-d6)δ155.8,154.5,144.6,135.9,135.0,132.8,126.9,122.1,117.2,113.2,112.8,112.4,103.6,83.8,82.1,56.3,47.2,47.0,46.7.HRMS(ESI)m/z:[M–I]+calculated for C19H20FN2O:311.1555,found:311.1551.
实施例5:19F-5FEE-F16的制备
合成方法同实施例1,不同在于,采用5-氟吲哚-3-甲醛代替5-溴吲哚-3-甲醛,和1,4-二甲基吡啶溴化物代替1,4-二甲基吡啶碘化物,重结晶得橘黄色固体产物0.26g。1HNMR(400MHz,DMSO-d6)δ8.70(d,J=6.6Hz,2H),8.20(d,J=16.3Hz,1H),8.14(d,J=6.9Hz,2H),8.04(s,1H),8.00(dd,J=10.1,2.5Hz,1H),7.69(dd,J=9.0,4.5Hz,1H),7.26(d,J=16.3Hz,1H),7.17(td,J=9.2,2.5Hz,1H),4.57–4.51(m,1H),4.47(t,J=5.1Hz,2H),4.43–4.39(m,1H),4.18(s,3H),3.82(t,J=5.0Hz,2H),3.72–3.65(m,1H),3.64–3.58(m,1H).13CNMR(121MHz,DMSO-d6)δ159.9,158.0,154.5,144.7,136.7,135.5,134.6,126.4,126.3,122.3,117.7,113.2,113.1,113.0,113.0,111.5,111.3,106.3,106.1,84.1,82.8,70.1,70.0,69.5,46.8,46.8.HRMS(ESI)m/z:[M-Br]+calculated for C20H21F2N2O:343.1617,found:343.1614.
实施例6:19F-5FEF-F16的制备
合成方法同实施例1,不同在于,采用5-氟吲哚-3-甲醛代替5-溴吲哚-3-甲醛,2-溴乙醇代替2-氯乙氧基乙醇,和1,4-二甲基吡啶高氯酸盐代替1,4-二甲基吡啶碘化物,重结晶得橘黄色固体产物0.20g。1H NMR(400MHz,DMSO-d6)δ8.71(d,J=6.9Hz,2H),8.21(d,J=16.3Hz,1H),8.15(d,J=7.0Hz,2H),8.07(s,1H),8.02(dd,J=10.1,2.5Hz,1H),7.69(dd,J=9.0,4.5Hz,1H),7.29(d,J=16.4Hz,1H),7.19(td,J=9.1,2.5Hz,1H),4.84(t,J=4.5Hz,1H),4.72(t,J=4.5Hz,1H),4.67(t,J=4.6Hz,1H),4.60(t,J=4.6Hz,1H),4.19(s,3H).13C NMR(126MHz,DMSO-d6)δ159.9,158.1,154.4,144.8,136.3,135.2,134.5,126.5,126.4,122.4,118.1,113.5,113.5,113.0,112.9,111.6,111.4,106.3,106.1,83.7,82.3,47.3,47.2,46.9.HRMS(ESI)m/z:[M–ClO4]+calculated for C18H17F2N2:299.1355,found:299.1353.
实施例7:19F-EE-F16的制备
合成方法同实施例1,不同在于,采用吲哚-3-甲醛代替5-溴吲哚-3-甲醛,重结晶得棕色固体产物0.26g。1H NMR(400MHz,DMSO-d6)δ8.67(d,J=6.7Hz,2H),8.22(d,J=16.2Hz,1H),8.18(dd,J=7.3,1.6Hz,1H),8.13(d,J=7.0Hz,2H),7.98(s,1H),7.66(dd,J=7.6,1.4Hz,1H),7.37–7.23(m,3H),4.57–4.52(m,1H),4.46(t,J=5.1Hz,2H),4.44–4.40(m,1H),4.17(s,3H),3.83(t,J=5.1Hz,2H),3.71–3.65(m,1H),3.63–3.58(m,1H).13C NMR(101MHz,DMSO-d6)δ154.5,144.7,137.9,136.1,135.7,125.9,123.4,122.1,121.9,121.1,117.4,113.2,111.7,84.3,82.6,70.1,70.0,69.5,46.7,46.4.HRMS(ESI)m/z:[M-I]+calculated for C20H22FN2O:325.1711,found:325.1708.
实施例8:19F-EF-F16的制备
合成方法同实施例1,不同在于,采用吲哚-3-甲醛代替5-溴吲哚-3-甲醛,2-溴乙醇代替2-氯乙氧基乙醇,和1,4-二甲基吡啶四氟硼酸盐代替1,4-二甲基吡啶碘化物,重结晶得棕色固体产物0.26g。1H NMR(400MHz,DMSO-d6)δ8.71(d,J=6.8Hz,2H),8.24(d,J=16.3Hz,1H),8.20(dd,J=7.3,1.5Hz,1H),8.15(d,J=6.9Hz,2H),8.01(s,1H),7.67(d,J=7.9Hz,1H),7.39–7.25(m,3H),4.85(t,J=4.6Hz,1H),4.73(t,J=4.6Hz,1H),4.68(t,J=4.7Hz,1H),4.61(t,J=4.6Hz,1H),4.18(s,3H).13C NMR(101MHz,DMSO-d6)δ154.0,144.2,137.4,135.4,134.8,125.5,125.5,123.1,121.8,121.5,120.6,117.3,113.1,111.2,83.1,81.8,46.5,46.4,46.3.HRMS(ESI)m/z:[M–BF4]+calculated for C18H18FN2:281.1449,found:281.1448.
实施例9:19F-5NEE-F16的制备
合成方法同实施例1,不同在于,采用5-二甲氨基吲哚-3-甲醛代替5-溴吲哚-3-甲醛,和1,4-二甲基吡啶高氯酸盐代替1,4-二甲基吡啶碘化物,重结晶得红色固体产物0.19g。1H NMR(400MHz,DMSO-d6)δ8.68(d,J=6.7Hz,2H),8.23(d,J=16.2Hz,1H),8.14(d,J=6.8Hz,2H),7.98(s,1H),7.65(d,J=2.5Hz,1H),7.46(d,J=8.9Hz,1H),7.18(d,J=16.2Hz,1H),6.99(dd,J=8.9,2.4Hz,1H),4.58–4.50(m,1H),4.46–4.38(m,3H),4.17(s,3H),3.88(s,3H),3.81(t,J=5.1Hz,2H),3.70–3.65(m,1H),3.63–3.57(m,1H),3.02(s,6H).13C NMR(101MHz,DMSO-d6)δ155.7,153.6,142.5,136.7,135.6,132.2,123.8,122.1,117.8,112.6,112.3,112.5,103.6,84.3,82.6,70.1,70.0,69.5,46.7,40.8.HRMS(ESI)m/z:[M–ClO4]+calculated for C22H27FN3O:368.2133,found:368.2132.
实施例10:19F-6FEF-F16的制备
合成方法同实施例1,不同在于,采用6-氟吲哚-3-甲醛代替5-溴吲哚-3-甲醛,2-溴乙醇代替2-氯乙氧基乙醇,和1,4-二甲基吡啶四氟硼酸盐代替1,4-二甲基吡啶碘化物,重结晶得棕色固体产物0.23g。1H NMR(400MHz,DMSO-d6)δ8.73(d,J=6.6Hz,2H),8.25–8.18(m,2H),8.16(d,J=6.9Hz,2H),8.02(s,1H),7.60(dd,J=10.2,2.4Hz,1H),7.33(d,J=16.3Hz,1H),7.16(td,J=9.2,2.4Hz,1H),4.84(t,J=4.6Hz,1H),4.72(t,J=4.5Hz,1H),4.65(t,J=4.7Hz,1H),4.58(t,J=4.7Hz,1H),4.20(s,3H).13C NMR(101MHz,DMSO-d6)δ161.2,158.9,154.3,144.8,138.3,138.2,135.6,135.3,122.6,122.4,122.3,122.2,118.3,113.7,110.2,110.0,98.6,98.3,83.8,82.1,47.2,47.0,46.9.HRMS(ESI)m/z:[M–BF4]+calculated for C18H17F2N2:299.1355,found:299.1352.
实施例11:19F-5CNEF-F16的制备
合成方法同实施例1,不同在于,采用5-氰基吲哚-3-甲醛代替5-溴吲哚-3-甲醛,2-溴乙醇代替2-氯乙氧基乙醇,重结晶得橘黄色固体产物0.19g。1H NMR(400MHz,DMSO-d6)δ8.82–8.74(m,3H),8.26(d,J=16.4Hz,1H),8.22–8.17(m,3H),7.88(d,J=8.6Hz,1H),7.71(dd,J=8.6,1.5Hz,1H),7.44(d,J=16.4Hz,1H),4.86(t,J=4.6Hz,1H),4.78–4.71(m,2H),4.67(t,J=4.6Hz,1H),4.22(s,3H).13C NMR(101MHz,DMSO-d6)δ154.0,145.0,139.4,136.2,134.0,126.2,126.1,125.7,122.7,120.6,119.7,114.0,113.0,103.9,83.8,82.2,47.2,47.0,47.0.HRMS(ESI)m/z:[M-I]+calculated for C19H17FN3:306.1402,found:306.1400.
实施例12:18F-5BEE-F16的放化标记
QMA柱依次使用10mL 1M碳酸氢钠水溶液和10mL去离子水通过并吹干,回旋加速器生产18F-氟离子富集在QMA柱上,用1mL淋洗液(含13mg K2.2.2和3mg碳酸钾,乙腈/水=9/1)将18F-氟离子从QMA柱上洗脱至5mL反应管中。吹入高纯氮气110℃加热共沸吹干,再加入1.5mL无水乙腈共沸吹干,重复两次保证反应体系无水。将2mg实施例1中制备的标记前体化合物3加入到反应管中,100℃密闭反应10分钟,反应管冷却后吸出倒入10mL水中,负载于C18 Sep-pak柱,后以20mL纯水淋洗杂质,再以1mL无水乙腈洗脱收集于反应管中。反应管经高纯氮气110℃加热共沸吹干,再加入2mg 1,4-二甲基吡啶碘化物、2μL哌啶和0.5mL无水乙腈,100℃密闭反应10分钟。冷却后加入1.5mL流动相稀释,0.22μm滤膜过滤后通过HPLC分离纯化,分离条件:岛津XBridge BEH C18反向柱(10×250mm,5μm);流动相:A=PBS水溶液,B=乙腈;梯度:0-5min,25%B,5-25min,25%B-80%B;流速:3mL/min。收集保留时间11.8min目标产物的流出液,再经氮吹干燥,得到18F-5BEE-F16。向其中加入1mL无菌生理盐水稀释备用。18F-5BEE-F16衰变校正后比活度103.2±30.6GBq/μmol,放化纯度如图2所示>98%。
实施例13:18F-5MEF-F16的放化标记
18F-5MEF-F16的放射性标记合成同实施例12,其投药量、反应条件一致。不同在于,使用实施例4中制备的标记前体化合物3,HPLC分离条件:岛津XBridge BEH C18反向柱(10×250mm,5μm);流动相:A=PBS水溶液,B=乙腈;梯度:0-5min,20%B,5-25min,20%B-75%B;流速:3mL/min。收集保留时间15.8min目标产物的流出液,再经氮吹干燥,加入1mL无菌生理盐水稀释备用。18F-5MEF-F16衰变校正后比活度为127.4±25.0GBq/μmol,放化纯度如图3所示>98%。
实施例14:18F-6FEF-F16的放化标记
18F-6FEF-F16的放射性标记合成同实施例12,不同在于采用的是1,4-二甲基吡啶四氟硼酸盐,使用实施例10中制备的标记前体化合物3,其投药量、反应条件和HPLC分离条件一致,收集保留时间11.5min目标产物的流出液,再经氮吹干燥,加入1mL无菌生理盐水稀释备用。18F-6FEF-F16衰变校正后比活度为93.8±12.6GBq/μmol,放化纯度如图4所示>98%。
试验例1:19F-F16化合物的光学性质
将上述实施例1-11制备的19F-F16化合物分别溶于PBS溶液,将溶液稀释配成10μmol/L的浓度,装于石英比色皿中,使用岛津UV-2600i分光光度计测定其吸收光谱,计算最大吸收波长;将上述测定好吸收光谱样品置于日立F-4500荧光光谱仪中,分别以其最大吸收波长为激发波长,测定其荧光发射光谱,计算最大发射波长;19F-F16化合物荧光量子产率测定参照文献(Adv.Funct.Mater.2014,24(5),635–643),以4-(二氰基亚甲基)-2-甲基-6-(对二甲氨基苯乙烯基)-4H-吡喃为荧光参照物,计算其在430nm下的荧光量子产率。实验结果见表1。
表1:19F-F16化合物的光学性质表
试验例2:18F-5MEF-F16的体外稳定实验
取实施例13制备的标记产物18F-5MEF-F16 100μCi分别加入到0.5mL的PBS溶液和胎牛血清FBS中。将两种溶液分别在37℃下分别孵育2h。在1h和2h孵育时间点,取一部分PBS样品直接进行HPLC稳定性检测。而对于FBS溶液,样品需先加入1mL乙腈使蛋白质沉淀下来,而后10000g/min离心5min,取部分上层清液,在HPLC上检测其稳定性。
实验结果如图5所示:18F-5MEF-F16在PBS和FBS溶液中都具有较好的稳定性,没有检测到杂质产生,且放化纯度均大于98%,表明18F-5MEF-F16在2h内是稳定的,适于进一步体内性质探究。
试验例3:18F-5MEF-F16在小鼠体内心肌灌注micro-PET/CT显像应用
取3只正常市售SPF级Balb/c小鼠分别经尾静脉注射100-150μCi剂量的实施例13制备的18F-5MEF-F16探针,用2.0%的异氟烷-氧气的混合气体维持小鼠麻醉状态,注射开始同步进行PET/CT扫描(西门子Inveon microPET),采集120min内动态显像图,勾画ROI,计算%ID/g。结果见图6和表2。
表2:18F-5MEF-F16在正常小鼠体内摄取分布及比值
如图6和表2所示:18F-5MEF-F16在正常小鼠中的生物分布结果显示,在心肌中有较高的初始摄取值和较好的滞留。注射10min后,心肌摄取值为8.50±0.32%ID/g,注射120min后,心肌摄取值仍有7.03±0.47%ID/g,在PET/CT显像中,心脏清晰可见。探针在肾脏具有较高的摄取值,2h内呈增加趋势,表明18F-5MEF-F16在小鼠体内主要通过肾脏排泄。18F-5MEF-F16与非靶如肌肉比值较高,10min时心脏/肌肉为4.86,有利于提高显像对比度,获得更好的诊断效果。
试验例4:18F-6FEF-F16在荷瘤小鼠体内micro-PET/CT显像应用
取3只市售SPF级Balb/c裸鼠,在右侧前肢腋下接种4T1细胞(小鼠乳腺癌细胞),待肿瘤直径约为7mm,分别经尾静脉注射100-150μCi剂量的实施例14制备的18F-6FEF-F16探针,用2.0%的异氟烷-氧气的混合气体维持小鼠麻醉状态,注射开始同步进行PET/CT扫描(西门子Inveon microPET),采集120min内动态显像图,勾画ROI,计算%ID/g。结果见图7和表3。
表3:18F-6FEF-F16在4T1荷瘤小鼠体内摄取分布及比值
如图7和表3所示:18F-6FEF-F16在荷瘤小鼠体内PET/CT显像表明,探针分子随时间明显浓聚于肿瘤部位,1h达到最高摄取值16.02±3.91%ID/g,明显高于肌肉、心脏、肺等脏器和组织,肿瘤/肌肉比值为7.49。PET/CT显像表明18F-6FEF-F16能特异性靶向肿瘤部位,具有较好的靶/非靶比值,肿瘤病灶部位清晰可见,具有较好的研究及应用前景。
试验例5:19F-F16在小鼠离体组织荧光显像应用
正常市售SPF级Balb/c小鼠分别经尾静脉注射~0.01mmol/kg剂量的实施例1-11制备的19F-F16探针,给药2h后取小鼠离体组织或器官,经铂金埃尔默IVIS LuminaⅢ小动物活体成像仪显像观察,结果见图8。
参见图8,部分19F-F16化合物在心脏组织分布明显,有较高靶/非靶比值,表明本发明所述化合可作为心肌灌注显像探针使用。
试验例6:19F-EE-F16在荷瘤小鼠活体成像应用
在市售SPF级Balb/c裸鼠右侧后肢接种4T1细胞,待肿瘤直径约为7mm,经尾静脉注射~0.01mmol/kg剂量的19F-EE-F16探针,铂金埃尔默IVIS LuminaⅢ小动物活体成像仪拍摄小鼠全身成像图,结果见图9。
参见图9,肿瘤部位能得到很好的成像效果,表明,本发明所述荧光探针在肿瘤诊断成像方面具有较好的应用前景。
以上所述仅为本发明优选实施例,对本发明而言仅具有说明性,但非限制性,相关领域普通技术人员可理解,在本发明权利要求所限定的精神和范围内可对其进行许多修改或者等效变更,但均属于本发明的保护范围。
Claims (8)
2.根据权利要求1所述的式I的化合物,其中,
X-为I-,Br-,BF4 -或ClO4 -;
R1和R2各自独立地选自氢、卤素、氰基、硝基、C1-C6烷氧基、-NR4R5,其中,-NR4R5选自二(C1-C6烷基)氨基、吡咯基、哌啶基、未取代或C1-C6烷基取代的哌嗪基、吗啉基。
5.根据权利要求1至4中任一项所述的式I化合物的制备方法,其制备路线如下:
所述方法通过如下方法一或方法二进行,
方法一
包括如下步骤:
(a)吲哚3-甲醛化合物1和Hal-(CH2CH2O)nC2H5OH发生亲核取代反应得到化合物2;
(b)化合物2与对甲苯磺酰氯发生酯化反应得到化合物3;
(c)化合物3在氨基聚醚(K2.2.2)存在下与18F-F-发生亲核取代反应得到18F取代的化合物18F-4;
(d)化合物18F-4与1,4-二甲基吡啶盐发生Knoevenagel缩合反应得到终产物18F-F16;
方法二
包括如下步骤:
(a)吲哚3-甲醛化合物1和Hal-(CH2CH2O)nC2H5OH发生亲核取代反应得到化合物2;
(b)化合物2与对甲苯磺酰氯发生酯化反应得到化合物3;
(e)化合物3与四丁基氟化铵发生亲核取代反应得到19F取代的化合物19F-4,
(f)化合物19F-4与1,4-二甲基吡啶盐发生Knoevenagel缩合反应得到终产物19F-F16;
其中n,R1,R2,X-分别如权利要求1-4中所定义,Hal表示卤素。
6.根据权利要求1至4中任一项所述的式I化合物作为线粒体靶向的正电子发射或荧光探针的应用。
7.根据权利要求6所述的应用,其中所述应用为所述的式I化合物作为线粒体靶向的正电子发射或荧光探针在心肌灌注和肿瘤显像中的应用。
8.根据权利要求6所述的应用,其中所述应用为所述的式I化合物作为线粒体靶向的正电子发射或荧光探针在制备心肌灌注PET显像剂或肿瘤PET显像剂或者在制备心肌灌注荧光显像剂或肿瘤荧光显像剂中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111476421.8A CN116217545B (zh) | 2021-12-06 | 2021-12-06 | 一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 |
PCT/CN2022/136793 WO2023104009A1 (zh) | 2021-12-06 | 2022-12-06 | 一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111476421.8A CN116217545B (zh) | 2021-12-06 | 2021-12-06 | 一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116217545A true CN116217545A (zh) | 2023-06-06 |
CN116217545B CN116217545B (zh) | 2024-01-02 |
Family
ID=86581130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111476421.8A Active CN116217545B (zh) | 2021-12-06 | 2021-12-06 | 一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116217545B (zh) |
WO (1) | WO2023104009A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150336993A1 (en) * | 2014-05-26 | 2015-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondria-targeted theranostic agents |
CN109293633A (zh) * | 2018-10-26 | 2019-02-01 | 山东大学 | 一种非反应型线粒体追踪荧光探针ivpi-12及其应用 |
CN109867591A (zh) * | 2019-03-12 | 2019-06-11 | 浙江大学 | 18f标记的aie荧光/pet双模态探针及其制备方法和应用 |
CN110577478A (zh) * | 2018-10-25 | 2019-12-17 | 南方医科大学南方医院 | 一种正电子探针及其制备方法与应用 |
WO2020150103A1 (en) * | 2019-01-15 | 2020-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Delocalized lipophilic cation compounds and methods of use thereof |
CN112028815A (zh) * | 2019-06-03 | 2020-12-04 | 中国药科大学 | 吲哚类衍生物及其医药用途 |
CN112375027A (zh) * | 2020-12-07 | 2021-02-19 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
-
2021
- 2021-12-06 CN CN202111476421.8A patent/CN116217545B/zh active Active
-
2022
- 2022-12-06 WO PCT/CN2022/136793 patent/WO2023104009A1/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150336993A1 (en) * | 2014-05-26 | 2015-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondria-targeted theranostic agents |
CN110577478A (zh) * | 2018-10-25 | 2019-12-17 | 南方医科大学南方医院 | 一种正电子探针及其制备方法与应用 |
CN109293633A (zh) * | 2018-10-26 | 2019-02-01 | 山东大学 | 一种非反应型线粒体追踪荧光探针ivpi-12及其应用 |
WO2020150103A1 (en) * | 2019-01-15 | 2020-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Delocalized lipophilic cation compounds and methods of use thereof |
CN109867591A (zh) * | 2019-03-12 | 2019-06-11 | 浙江大学 | 18f标记的aie荧光/pet双模态探针及其制备方法和应用 |
CN112028815A (zh) * | 2019-06-03 | 2020-12-04 | 中国药科大学 | 吲哚类衍生物及其医药用途 |
CN112375027A (zh) * | 2020-12-07 | 2021-02-19 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2023104009A1 (zh) | 2023-06-15 |
CN116217545B (zh) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101555232B (zh) | 氟-18标记哒嗪酮类化合物及制备方法和应用 | |
CN109320536B (zh) | 一种基于Aza-BODIPY的近红外二窗的荧光探针及其制备与应用 | |
KR102214462B1 (ko) | 황화수소 검출용 방사성 프로브 | |
EA017713B1 (ru) | [f-18]-меченая l-глутаминовая кислота, [f-18]-меченый l-глутамин, их производные и их применение, а также способ их получения | |
US8487077B2 (en) | Simplified one-pot synthesis of [18F]SFB for radiolabeling | |
CN111592482B (zh) | 一种pH可逆激活型光热/光动力/荧光一体化探针分子 | |
CN109867591A (zh) | 18f标记的aie荧光/pet双模态探针及其制备方法和应用 | |
CN113200964B (zh) | 18f标记的egfr正电子显像剂及其制备方法与应用 | |
CN110183493B (zh) | 一种99m锝标记配合物及其在诊断非小细胞肺癌中的应用 | |
CN113861190B (zh) | 一种靶向p2x7受体的pet显像剂及其制备方法、组合物及用途 | |
CN103254139B (zh) | 新型18f标记4-氨基喹唑啉类衍生物及其制备方法和肿瘤pet显像应用 | |
CN116217545B (zh) | 一类线粒体靶向的正电子发射或荧光探针、其制备方法及应用 | |
CN113149966A (zh) | Nir/pet双模态造影剂及其制备方法与应用 | |
WO2023245857A1 (zh) | 一种辣椒素衍生化光敏剂及其制备方法与应用 | |
CN114315795B (zh) | 68Ga标记的靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法 | |
CN114031652B (zh) | 一种含环己烷的葡萄糖衍生物及其应用 | |
Chen et al. | Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection | |
CN113583066B (zh) | 一种甘露糖衍生物及其应用 | |
CN106631908B (zh) | 一种放射性碘标记方法 | |
CN108586524B (zh) | 氟代氧化膦类化合物及其在正电子发射显像中的应用 | |
JP6037330B2 (ja) | 11c−標識チアミン及びその誘導体、11c−標識フルスルチアミン、チアミン前駆体、並びにpet用プローブ及びそれらを用いたイメージング方法 | |
CN110577478A (zh) | 一种正电子探针及其制备方法与应用 | |
CN109438265B (zh) | 一种与棕色脂肪组织具有亲和力的化合物及其制备方法和应用 | |
CN110818636A (zh) | 一种化合物或其盐及其应用和合成方法 | |
CN112250680B (zh) | 一种新型黄连素衍生物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |